Hyneck M L, Smith P C, Munafo A, McDonagh A F, Benet L Z
Department of Pharmacy, School of Pharmacy, University of California, San Francisco 94143-0446.
Clin Pharmacol Ther. 1988 Jul;44(1):107-14. doi: 10.1038/clpt.1988.120.
The pharmacokinetics and irreversible plasma protein binding of tolmetin were studied in six healthy subjects after the administration of a single, 400 mg dose of tolmetin. With HPLC analysis, tolmetin, tolmetin glucuronide, and the isomers of tolmetin glucuronide, which result from intramolecular acyl migration in vivo, were detected in the plasma up to 4 hours after administration, whereas these conjugates were present in the urine up to 24 hours. Irreversible binding of tolmetin to plasma proteins occurred in all subjects. Irreversible binding exhibited a better correlation with exposure to tolmetin glucuronide (r = 0.5618) and the isomers of tolmetin glucuronide (r = 0.8200) than with exposure to tolmetin (-0.3635). This is consistent with the hypothesis that covalent binding occurs via the acyl glucuronide.
在六名健康受试者单次服用400mg托美汀后,对其药代动力学和不可逆血浆蛋白结合情况进行了研究。通过高效液相色谱分析,给药后4小时内可在血浆中检测到托美汀、托美汀葡糖醛酸苷以及体内分子内酰基迁移产生的托美汀葡糖醛酸苷异构体,而这些缀合物在尿液中可存在长达24小时。所有受试者均出现托美汀与血浆蛋白的不可逆结合。不可逆结合与托美汀葡糖醛酸苷(r = 0.5618)和托美汀葡糖醛酸苷异构体(r = 0.8200)的暴露量相关性优于与托美汀暴露量的相关性(r = -0.3635)。这与共价结合通过酰基葡糖醛酸发生的假说一致。